Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2015 Aug 17;5(8):e008378.
doi: 10.1136/bmjopen-2015-008378.

Exploring threats to generalisability in a large international rehabilitation trial (AVERT)

Collaborators, Affiliations
Randomized Controlled Trial

Exploring threats to generalisability in a large international rehabilitation trial (AVERT)

Julie Bernhardt et al. BMJ Open. .

Abstract

Objective: The purpose of this paper is to examine potential threats to generalisability of the results of a multicentre randomised controlled trial using data from A Very Early Rehabilitation Trial (AVERT).

Design: AVERT is a prospective, parallel group, assessor-blinded randomised clinical trial. This paper presents data assessing the generalisability of AVERT.

Setting: Acute stroke units at 44 hospitals in 8 countries.

Participants: The first 20,000 patients screened for AVERT, of whom 1158 were recruited and randomised.

Model: We use the Proximal Similarity Model, which considers the person, place, and setting and practice, as a framework for considering generalisability. As well as comparing the recruited patients with the target population, we also performed an exploratory analysis of the demographic, clinical, site and process factors associated with recruitment.

Results: The demographics and stroke characteristics of the included patients in the trial were broadly similar to population-based norms, with the exception that AVERT had a greater proportion of men. The most common reason for non-recruitment was late arrival to hospital (ie, >24 h). Overall, being older and female reduced the odds of recruitment to the trial. More women than men were excluded for most of the reasons, including refusal. The odds of exclusion due to early deterioration were particularly high for those with severe stroke (OR=10.4, p<0.001, 95% CI 9.27 to 11.65).

Conclusions: A model which explores person, place, and setting and practice factors can provide important information about the external validity of a trial, and could be applied to other clinical trials.

Trial registration number: Australian New Zealand Clinical Trials Registry (ACTRN12606000185561) and Clinicaltrials.gov (NCT01846247).

Keywords: Generalisability; Proximal Similarity Model; Randomised Control Trial; Rehabilitation.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Proximal similarity framework applied to the AVERT trial: a model for conceptualising the dimensions along which the sample of patients may be similar to the target population. Each dimension (person, place and setting and practice) is affected by specific factors which may threaten external validity (AVERT, A Very Early Rehabilitation Trial; ICU, intensive care unit).
Figure 2
Figure 2
Relationship between trial inclusion/exclusion criteria and screening log categories (AVERT, A Very Early Rehabilitation Trial).
Figure 3
Figure 3
Methods of explorative analysis using the first reason for non-recruitment (arrived after 24 h) as an example. Bold boxes indicate data grouping. Analyses were repeated for all 10 reasons for non-recruitment, with four patient demographic and clinical factors. Trial site and month of trial were controlled for in each analysis (ICU, intensive care unit; mRS, modified Rankin Scale).

References

    1. Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions. West Sussex, England: The Cochrane Collaboration, 2008.
    1. Rothwell PM. External validity of randomised controlled trials: “To whom do the results of this trial apply?” Lancet 2005;365:82–93. 10.1016/S0140-6736(04)17670-8 - DOI - PubMed
    1. Moher D, Hopewell S, Schulz KF et al. . CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol 2010;63:e1–e37. 10.1016/j.jclinepi.2010.03.004 - DOI - PubMed
    1. Glasgow RE, Green LW, Klesges LM et al. . External validity: we need to do more. Ann Behav Med 2006;31:105–8. 10.1207/s15324796abm3102_1 - DOI - PubMed
    1. Rothwell PM. Commentary: external validity of results of randomized trials: disentangling a complex concept. Int J Epidemiol 2010;39:94–6. 10.1093/ije/dyp305 - DOI - PubMed

Publication types

Associated data